Results 201 to 210 of about 156,017 (326)

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Data Sheet 1_The association between test anxiety, learning strategies, and open-label placebo effects on academic test performance: a secondary analysis of a randomized controlled trial.xlsx

Elisa Frisaldi (5075489), Julian Kleine-Borgmann (12281675), Helena Hartmann (10708179), Sven Benson (117120), Ulrike Bingel (242906), Katharina Schmidt (693864)   +5 more
openalex   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

How orthopedic surgeons view open label placebo pills: Ethical and effective, but opposed to personal use

, 2021
Michael H. Bernstein, Maayan Rosenfield, Nathaniel Fuchs, Molly Magill, Charlotte Blease, Francesca L. Beaudoin, Josiah D. Rich, Karolina Wartolowska, Richard M. Terek   +8 more
openalex   +2 more sources

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial [PDF]

, 2015
Milagritos D. Tapia, Samba O. Sow, Kirsten E. Lyke, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Awa Traoré, Flanon Coulibaly, Mamoudou Kodio, Uma Onwuchekwa, Marcelo B. Sztein, Rezwanul Wahid, James D. Campbell, Marie‐Paule Kieny, Vasee Moorthy, Egeruan B. Imoukhuede, Tommy Rampling, François Roman, Iris De Ryck, Abbie R. Bellamy, Len Dally, Olivier Tshiani Mbaya, Aurélie Ploquin, Yan Zhou, Daphne A. Stanley, Robert T. Bailer, Richard A. Koup, Mario Roederer, Julie E. Ledgerwood, Adrian V. S. Hill, W. Ripley Ballou, Nancy J. Sullivan, Barney S. Graham, Myron M. Levine   +33 more
openalex   +1 more source

Design(ing) and the Placebo Effect—A Productive Idea [PDF]

, 2018
Drayson, HE
core   +2 more sources

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source